Published in final edited form as:

Bioorg Med Chem Lett. 2014 December 15; 24(24): 5663–5665. doi:10.1016/j.bmcl.2014.10.070.

Derivatization of ($\pm$) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2

Amit Kumar^a, Su-Tang Lo^a, Orhan K. Öz^a, and Xiankai Sun^{a,b}

^aDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA

^bAdvanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA

Abstract

Dihydrotetrabenazine (DTBZ) derivatized from (+) Tetrabenazine (TBZ) has been used for imaging the expression of VMAT2 when labeled with ¹¹C ($t_{1/2}$ = 20.3 min.) or ¹⁸F ($t_{1/2}$ = 110 min.) in neurodegenerative diseases or pancreatic beta-cell. Because ¹¹C or ¹⁸F radiolabels are only available in the proximity of a biomedical cyclotron facility, here we report our work of derivatizing (+) and (–) DTBZ using a ⁶⁴Cu-specific bifunctional chelator scaffold (⁶⁴Cu: $t_{1/2}$ = 12.7 h) for the preparation of long-lived VMAT2 targeted radiotracers, ⁶⁴Cu-CB-TE2A-(+)-DTBZ and ⁶⁴Cu-CB-TE2A-(–)-DTBZ. The specific VMAT2 binding affinity of ⁶⁴Cu-CB-TE2A-(+)-DTBZ measured using rat brain homogenate or porcine islets was not compromised by our chemical modifications while that of its (–) counterpart remained low as in ¹¹C or ¹⁸F labeled ($\pm$) DTBZ.

Keywords

Positron Emission Tomography; VMAT2; Copper-64; Bifunctional Chelator

Vesicular monoamine transporter (VMAT2) is a membrane protein responsible for transporting monoamines (dopamine, serotonin, norepinephrine, epinephrine and histamine) from within the neuron into the storage granules (vesicles). It has been linked with several of neurological and psychiatric disorders such as Parkinson's disease. The level of VMAT2 expression provides an understanding of neurological and psychiatric diseases. To date, Positron Emission Tomography (PET) imaging of VMAT2 density in the basal ganglia area

© 2014 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Material

Supplementary data associated with synthesis and evaluation is available.

of the brain using [^{11}C](+)-dihydrotetrabenazine ([^{11}C] (+)-DTBZ) has been successfully applied to the clinical diagnosis of Parkinson's disease and neurodegenerative diseases.^{1,2}

Recently it has been demonstrated that VMAT2 binding sites are expressed predominantly on the beta cells in the islets of Langerhans.^{3,4} Therefore, VMAT2 based ligands have been used for imaging beta cell mass (BCM). Of them, [^{11}C] (+)-DTBZ has been used for PET imaging of VMAT2 binding sites in the pancreas of rodents, primates, and humans.^{4,5}

Currently, ^{11}C and ^{18}F are the only PET nuclides reported for the development of DTBZ targeted imaging probes (Figure 1). However, the short half-lives of these two radioisotopes (^{11}C $t_{1/2}$ =20.3 m, ^{18}F $t_{1/2}$ =109 m) limits their application as the chemical procedures to incorporate these isotopes must be carried out in the proximity of a biomedical cyclotron. Among nonstandard PET nuclides, ^{64}Cu ($t_{1/2}$ =12.7 h; β^+ 0.653 MeV, 17.4%) has drawn considerable interest in PET research owing to its low positron range, commercial availability, and reasonably long decay half-life. In this work, we derivatized DTBZ for radiolabeling with ^{64}Cu in order to construct a relatively long-lived PET imaging probe for noninvasive assessment of VMAT2 expression, preferably in the pancreatic beta cell by conjugating VMAT2 targeting (+)-DTBZ to a bifunctional chelator scaffold⁶ derived from 2,2'-(1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diyl)diacetic acid (CB-TE2A), an ideal Cu(II) chelator for PET imaging. In vitro assays of the resulted ^{64}Cu radiotracers were performed on rat brain homogenates and porcine islets.

The synthesis of CB-TE2A-DTBZ conjugate was accomplished by two parts of chemistry (supplementary information). The first encompassed the synthesis and resolution of DTBZ while the second dealt with the synthesis of CB-TE2A conjugate and its subsequent deprotection. There are two known primary methods for the synthesis of DTBZ: the cyclization of tetrahydro-isoquinoline derivatives⁷ or the condensation of a 3,4-dihydro-isoquinoline derivative with β -amino ketone.⁸ We followed the later method and synthesized DTBZ by condensation of 6,7-Dimethoxy-3,4-dihydro-quinoline⁹ and β -amino ketone⁸ according to the published literature.¹⁰ Resolution of ($\pm$) DTBZ was carried out based on a published procedure.^{10,11} The separation was based on the existence of an interconversion between benzo[*a*]quinolizine and isoquinolinium upon exposure to an acid. Amino functional group was then introduced on the DTBZ molecule by following a published procedure.¹² The CB-TE2A-DTBZ conjugate was then synthesized by acid-amine conjugation via carbodiimide chemistry. The CB-TE2A scaffold containing γ -carboxylic acid was reacted with amine terminated DTBZ derivatives (**4** and **6**) in DMF as solvent in the presence of ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as coupling agent and triethylamine as proton scavenger to give protected DTBZ conjugates **5** and **7** (Scheme 1). Finally, the t-butyl carboxylate group was removed using trifluoroacetic acid and dichloromethane mixture (1:1) to provide **1** and **2**, each containing two free carboxylic acids to ensure the biological stability of the ^{64}Cu label.

The ^{64}Cu labeling was performed using ammonium acetate buffer (0.4 M) under mild acidic condition (pH = 6.5)⁶ for all the conjugates. Reaction was carried out at 85 °C for 30 min. Both conjugates were radiolabeled with ^{64}Cu in > 60% yields. The ^{64}Cu -labeled conjugates were purified in one-step using a preactivated C-18 Sep-Pak light cartridge. The

radiochemical purity of the ^{64}Cu -labeled conjugates after cartridge purification was >99% as determined by radio-TLC and radio-HPLC. The specific activity of ^{64}Cu -CB-TE2A-(+)-DTBZ and ^{64}Cu -CB-TE2A-(−)-DTBZ was in the range 33–44 MBq/nmol. Both ^{64}Cu -labeled conjugates were eluted from HPLC about 1 min earlier than their respective cold counterparts.

The in vitro binding affinities of CB-TE2A-(+)-DTBZ and CB-TE2A-(−)-DTBZ were determined by a competitive binding assay using rat brain homogenates with ^{64}Cu -CB-TE2A-(+)-DTBZ as the VMAT2 radio-ligand. The rat brain homogenates were obtained from the striatum regions of rat brains, which express VMAT2. While both CB-TE2A-(+)-DTBZ and CB-TE2A-(−)-DTBZ inhibited the radioligand binding in a dose-dependent manner, the former had a much more pronounced effect than the latter (Figure 2a). The calculated half maximal inhibitory concentration (IC_{50}) values of CB-TE2A-(+)-DTBZ and CB-TE2A-(−)-DTBZ expressed by the 50% inhibitory concentration to the binding of ^{64}Cu -CB-TE2A-(+)-DTBZ to the homogenates were 16.8 ± 6.85 nM and 253.22 ± 107.77 nM, respectively. In comparison, the reported IC_{50} values of (+)-DTBZ and (−)-DTBZ measured using the rat brain striatum were 0.97 ± 0.48 nM and 2.2 ± 0.3 μM , respectively.¹³ The competitive binding assay result clearly demonstrates the anticipated higher VMAT2 binding affinity of CB-TE2A-(+)-DTBZ as compared to its (−) counterpart. In addition, it shows that the conjugation of (+) DTBZ to CB-TE2A does not significantly alter the binding affinity of the parent compound.

To test the feasibility of using ^{64}Cu -CB-TE2A-(+)-DTBZ for pancreatic beta cell imaging, we performed an ex vivo binding assay of ^{64}Cu -CB-TE2A-(+)-DTBZ and ^{64}Cu -CB-TE2A-(−)-DTBZ using freshly isolated porcine islets. For the assay, a fixed amount of radioactivity of ^{64}Cu -CB-TE2A-(+)-DTBZ and ^{64}Cu -CB-TE2A-(−)-DTBZ was added to varying numbers of islets. After incubation and washing, the activity trapped in the islets was measured. The results of the assay are shown in Figure 2b. The amount of radioactivity of ^{64}Cu -CB-TE2A-(+)-DTBZ bound to the islets was much higher than that of ^{64}Cu -CB-TE2A-(−)-DTBZ, indicating the preferential islet uptake of ^{64}Cu -CB-TE2A-(+)-DTBZ, a determinant for BCM imaging probe development.

Taken together, we successfully derivatized ($\pm$) DTBZ for ^{64}Cu labeling without significantly compromising their VMAT2 binding affinity. Between the two conjugates, CB-TE2A-(+)-DTBZ exhibited the desired preferential accumulation in freshly isolated porcine islets, which may potentiate its use as a VMAT2-targeted imaging agent for noninvasive assessment of pancreatic beta-cell imaging or other VMAT2 expressing non-brain organs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was partially supported by a grant from the National Institutes of Health (R01 DK092163) and the Dr. Jack Krohmer Professorship Funds.

References and notes

1. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. *J. Nucl. Med.* 2005; 46:936. [PubMed: 15937303]
2. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA. *J. Cereb. Blood Flow Metab.* 2006; 26:1198. [PubMed: 16421508]
3. Maffei A, Liu Z, Witkowski P, Moschella F, Pozzo GD, Liu E, Herold K, Winchester RJ, Hardy MA, Harris PE. *Endocrinology.* 2004; 145:4513. [PubMed: 15231694]
4. Harris P, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. *J. Mol. Med.* 2008; 86:5. [PubMed: 17665159]
5. Souza F, Freeby M, Hultman K, Simpson N, Herron A, Witkowsky P, Liu E, Maffei A, Harris PE. *Curr. Med. Chem.* 2006; 13:2761. [PubMed: 17073627]
6. Liu W, Hao G, Long MA, Anthony T, Hsieh J-T, Sun X. *Angew. Chem. Int. Ed.* 2009; 48:7346.
7. Brossi A, Lindlar H, Walter M, Schnider O. *Helv. Chim. Acta.* 1958; 41:119.
8. Openshaw HT, Whittaker N. *J. Chem. Soc.* 1963:1449.
9. Murahashi S-I, Naota T, Taki H. *Chem. Commun.* 1985:613.
10. Yu Q-S, Luo W, Deschamps J, Holloway HW, Kopajtic T, Katz JL, Brossi A, Greig NH. *ACS Med. Chem. Lett.* 2010; 1:105. [PubMed: 20694189]
11. Yao Z, Wei X, Wu X, Katz JL, Kopajtic T, Greig NH, Sun H. *Eur. J. Med. Chem.* 2011; 46:1841. [PubMed: 21396745]
12. Zhu L, Liu J, Kung HF. *Bioorg. Med. Chem. Lett.* 2009; 19:5026. [PubMed: 19632829]
13. Kilbourn M, Lee L, Borghat TV, Jewett D, Frey K. *Eur. J. Pharmacol.* 1995; 278:249. [PubMed: 7589162]

Figure 1.

Structures of CB-TE2A conjugate of (+) DTBZ (**1**) and (-) DTBZ (**2**). Also depicted are the structures of ^{11}C and ^{18}F labelled (+) DTBZ.

Figure 2.

(a) Competitive binding assay using rat brain homogenates with ^{64}Cu -CB-TE2A-(+)-DTBZ as the VMAT2 radioligand. (b) Ex vivo binding assay of ^{64}Cu -CB-TE2A-(+)-DTBZ and ^{64}Cu -CB-TE2A-(-)-DTBZ using freshly isolated porcine islets.

Scheme 1.
Synthetic Routes to amino derivative of CB-TE2A-DTBZ conjugate